The most exciting
news in the Evans Family is the birth of our second grandchild on April 15th. Naomi Jean Evans came into this world very
quickly. We received a call around 5am
saying Matt and Randi were going to the hospital and at 8:15 she was born. Donna flew up that day and I followed the
next day. We stayed in Seattle at Matt
& Randi’s for a week and it was a
real treat to be able to spend time with them, and the new family member, Naomi.
There was an interesting post 2 weeks ago by a prominent CLL expert named Dr. Susan O’Brien. In this post she argues that there is no sensible reason for not allowing the 180 of us who were on the Clinical Trial and received Ofatumumab to now receive the trial drug, Ibrutinib. The interesting thing is that ALL of the major CLL experts in the U.S. agree with her. The problem here is the FDA. They follow guidelines that are completely out of touch with reality. It is well documented that Ofatumumab will give CLL patients a partial short lived remission. So when I start to relapse, wouldn’t it make sense to move me over to the Ibrutinib which has had a 95% success rate in controlling CLL. Although the trial officially closed in April, the documented results may not be available for over a year. So, I suppose that you hope and pray that you can wait that long and have the drug approved for general distribution. Seems like a crazy system to me.
http://www.ascopost.com/issues/may-1,-2013/ibrutinib-cll-trial-where-is-the-equipoise.aspx
So which category did you fall into? Already knew what equipoise meant, didn't know, but looked it up, or didn't care? I'm not doing your work for you. Figure it out.
I
had an ‘end of trial’ CT Scan in March and results show that my lymph nodes
have basically stayed the same (after initially shrinking at the beginning of
the trial). I am scheduled for another
bone marrow biopsy in June to see how the drug impacted the marrow. Then, in July, I will see Dr. Kipps and
figure out what my next steps might be.
I’m still feeling well and enjoying life.
There was an interesting post 2 weeks ago by a prominent CLL expert named Dr. Susan O’Brien. In this post she argues that there is no sensible reason for not allowing the 180 of us who were on the Clinical Trial and received Ofatumumab to now receive the trial drug, Ibrutinib. The interesting thing is that ALL of the major CLL experts in the U.S. agree with her. The problem here is the FDA. They follow guidelines that are completely out of touch with reality. It is well documented that Ofatumumab will give CLL patients a partial short lived remission. So when I start to relapse, wouldn’t it make sense to move me over to the Ibrutinib which has had a 95% success rate in controlling CLL. Although the trial officially closed in April, the documented results may not be available for over a year. So, I suppose that you hope and pray that you can wait that long and have the drug approved for general distribution. Seems like a crazy system to me.
http://www.ascopost.com/issues/may-1,-2013/ibrutinib-cll-trial-where-is-the-equipoise.aspx
Terry